Universität zu Köln

Jakobs, Florian, Jeck, Julia, Ahmadi, Paymon, Kron, Anna and Kron, Florian ORCID: 0000-0003-4907-7490 (2022). Health economic analysis of third-line interventions in diffuse large B-cell lymphomas in Germany: applying the efficiency frontier. Cost Effect. Resour Alloc., 20 (1). LONDON: BMC. ISSN 1478-7547

Full text not available from this repository.

Abstract

BackgroundIn the past decades, highly innovative treatments in the field of diffuse large B-cell lymphoma (DLBCL) became available in clinical practice. The aim of this study was to assess the cost-benefit relation of third-line interventions in DLBCL from a German payer perspective. MethodsClinical benefit of allogeneic stem cell transplantation (alloSCT), chimeric antigen receptor T cells therapy (CAR T) [tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel)] and best supportive care (BSC) was assessed in terms of median overall survival (median OS) derived from a systematic literature review in PubMed. Real-world treatment costs were retrieved from the university hospitals Cologne and Hamburg-Eppendorf. The cost-benefit relation was analysed using the efficiency frontier concept. ResultsMedian OS varied from 6.3 months in BSC to 23.5 months in CAR T (axi-cel), while median real-world treatment costs ranged likewise widely from euro26,918 in BSC to euro340,458 in CAR T (axi-cel). Shown by the efficiency frontier, alloSCT and axi-cel were found as most efficient interventions. ConclusionThe efficiency frontier supports the pricing of innovative therapies, such as third-line interventions in DLBCL, in relation to appropriate comparators. Yet, studies with longer follow-up periods are needed to include studies with unreached median OS and to reflect experiences gained with CAR T in clinical practice.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Jakobs, Florian UNSPECIFIED UNSPECIFIED UNSPECIFIED Jeck, Julia UNSPECIFIED UNSPECIFIED UNSPECIFIED Ahmadi, Paymon UNSPECIFIED UNSPECIFIED UNSPECIFIED Kron, Anna UNSPECIFIED UNSPECIFIED UNSPECIFIED Kron, Florian UNSPECIFIED orcid.org/0000-0003-4907-7490 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-682279
DOI:	10.1186/s12962-022-00400-0
Journal or Publication Title:	Cost Effect. Resour Alloc.
Volume:	20
Number:	1
Date:	2022
Publisher:	BMC
Place of Publication:	LONDON
ISSN:	1478-7547
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language COST-EFFECTIVENESS ANALYSIS; AXICABTAGENE CILOLEUCEL; COMPARING EFFICACY; PREINFUSION PERIOD; TISAGENLECLEUCEL; SAFETY; DLBCL; CHEMOTHERAPY; STANDARD; MODEL Multiple languages Health Policy & Services Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/68227